Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome

References

• Yang N, Liu J, Liu J, et al. Performance on management strategies with Class I Recommendation and a level of evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: findings from the improving care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project. Am Heart J. 2019;212:80–90.30981036
   PubMed Web of Science ®Google Scholar
• Bonaventura A, Vecchié A, Abbate A, Montecucco F. Neutrophil extracellular traps and cardiovascular diseases: an update. Cells. 2020;9(1):231. doi:10.3390/cells9010231
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–1361. doi:10.1038/nature0893820428172
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594–604. doi:10.1161/CIRCULATIONAHA.110.98277721282498
   PubMed Web of Science ®Google Scholar
• Wang L, Qu P, Zhao J, Chang Y. NLRP3 and downstream cytokine expression elevated in the monocytes of patients with coronary artery disease. Arch Med Sci. 2014;10(4):791–800. doi:10.5114/aoms.2014.4487125276166
   PubMed Web of Science ®Google Scholar
• Deng M, Brickey WJ, Guo H, et al. Platelet activating factor as a novel danger signal for activation of NLRP3 inflammasome. J Immunol. 2018;200(1 Supplement):113–115.
   Web of Science ®Google Scholar
• Berger JS. Oral antiplatelet therapy for secondary prevention of acute coronary syndrome. Am J Cardiovasc Drugs. 2018;18(6):457–472. doi:10.1007/s40256-018-0291-229987548
   PubMed Web of Science ®Google Scholar
• Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289–1299. doi:10.1161/CIRCULATIONAHA.118.03801030586730
   PubMed Web of Science ®Google Scholar
• Schrör K, Huber K. Platelets, inflammation and anti-inflammatory drugs in ACS and CAD. Thromb Haemost. 2015;114(3):446–448. doi:10.1160/TH15-08-063226288949
   PubMed Web of Science ®Google Scholar
• Heger LA, Hortmann M, Albrecht M, et al. Inflammation in acute coronary syndrome: expression of TLR2 mRNA is increased in platelets of patients with ACS. PLoS One. 2019;14(10):e0224181. doi:10.1371/journal.pone.022418131644579
   PubMed Web of Science ®Google Scholar
• Orrem HL, Nilsson PH, Pischke SE, et al. IL-6 Receptor inhibition by tocilizumab attenuated expression of C5a Receptor 1 and 2 in Non-ST-elevation myocardial infarction. Front Immunol. 2018;9:2035. doi:10.3389/fimmu.2018.0203530258440
   PubMed Web of Science ®Google Scholar
• Wu H, Qian J, Sun A, Wang Q, Ge J. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Circ J. 2012;76(12):2773–2778. doi:10.1253/circj.CJ-12-063522971905
   PubMed Web of Science ®Google Scholar
• Oz TK, Özbilgin N, Sungur A, et al. Prevalence of metabolic syndrome in young patients with ST-elevation myocardial infarction. Int J Cardiovasc Acad. 2018;4(3):53.
   Google Scholar
• Lopes RD, de Barros ESPGM, Damiani LP, et al. Major adverse cardiovascular events after 12 months among patients with acute coronary syndrome receiving loading doses of atorvastatin prior to planned PCI. JAMA. 2020;323(8):787–789. doi:10.1001/jama.2020.011832096839
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Baldrighi M, Mallat Z, Li X. NLRP3 inflammasome pathways in atherosclerosis. Atherosclerosis. 2017;267:127–138. doi:10.1016/j.atherosclerosis.2017.10.02729126031
   PubMed Web of Science ®Google Scholar
• Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63(4):316–322. doi:10.1097/FJC.000000000000005324336017
   PubMed Web of Science ®Google Scholar
• Liu Y, Lian K, Zhang L, et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2014;109(5):415. doi:10.1007/s00395-014-0415-z25015733
   PubMed Web of Science ®Google Scholar
• Szekely Y, Arbel YJ. A review of Interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018;7(1):25–44.29417406
   PubMed Web of Science ®Google Scholar
• Mahtta D, Sudhakar D, Koneru S, et al. Targeting inflammation after myocardial infarction. Curr Cardiol Rep. 2020;22(10):110. doi:10.1007/s11886-020-01358-232770365
   PubMed Web of Science ®Google Scholar
• Bullenkamp J, Mengoni V, Kaur S, et al. Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. Cardiovasc Res. 2020. doi:10.1093/cvr/cvaa202
   Web of Science ®Google Scholar
• Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–384. doi:10.1093/eurheartj/ehu27225079365
   PubMed Web of Science ®Google Scholar
• Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116(7):1254–1268. doi:10.1161/CIRCRESAHA.116.30231725814686
   PubMed Web of Science ®Google Scholar
• Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–1400. doi:10.1016/j.amjcard.2013.01.28723453459
   PubMed Web of Science ®Google Scholar
• Murthy P, Durco F, Miller-Ocuin JL, et al. The NLRP3 inflammasome and bruton’s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. Biochem Biophys Res Commun. 2017;483(1):230–236. doi:10.1016/j.bbrc.2016.12.16128034752
   PubMed Web of Science ®Google Scholar
• Paramel Varghese G, Folkersen L, Strawbridge RJ, et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc. 2016;5(5):e003031. doi:10.1161/JAHA.115.00303127207962
   PubMed Web of Science ®Google Scholar
• Qiao J, Wu X, Luo Q, et al. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis. Haematologica. 2018;103(9):1568–1576. doi:10.3324/haematol.2018.19170029794149
   PubMed Web of Science ®Google Scholar
• Haneklaus M, O’Neill LA. NLRP3 at the interface of metabolism and inflammation. Immunol Rev. 2015;265(1):53–62. doi:10.1111/imr.1228525879283
   PubMed Web of Science ®Google Scholar
• Ju HY, Kim JK, Hur SM, et al. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease? Platelets. 2015;26(2):143–147. doi:10.3109/09537104.2014.89017924679226
   PubMed Web of Science ®Google Scholar
• Koh YY, Kim HH, Choi DH, et al. Relation between the change in mean platelet volume and clopidogrel resistance in patients undergoing percutaneous coronary intervention. Curr Vasc Pharmacol. 2015;13(5):687–693. doi:10.2174/157016111266614101712111825322834
   PubMed Web of Science ®Google Scholar
• Colkesen Y, Coskun I, Muderrisoglu H. The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. Platelets. 2013;24(4):263–266. doi:10.3109/09537104.2012.68210622647033
   PubMed Web of Science ®Google Scholar
• Haungsaithong R, Udommongkol C, Nidhinandana S, et al. The changes in mean platelet volume after using of antiplatelet drugs in acute ischemic stroke: a randomized controlled trial. J Med Assoc Thai. 2015;98(9):852–857.26591394
   PubMedGoogle Scholar
• Martin JF, Plumb J, Kilbey RS, Kishk YT. Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed). 1983;287(6390):456–459. doi:10.1136/bmj.287.6390.456
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Tall AR. Disordered haematopoiesis and athero-thrombosis. Eur Heart J. 2016;37(14):1113–1121.26869607
   PubMed Web of Science ®Google Scholar
• Carbone S, Mauro AG, Prestamburgo A, et al. An Orally Available NLRP3 inflammasome inhibitor prevents western diet-induced cardiac dysfunction in mice. J Cardiovasc Pharmacol. 2018;72(6):303–307. doi:10.1097/FJC.000000000000062830422890
   PubMed Web of Science ®Google Scholar
• Hamada S, Schroeder J, Hoffmann R, et al. Prediction of outcomes in patients with chronic ischemic cardiomyopathy by layer-specific strain echocardiography: a proof of concept. J Am Soc Echocardiography. 2016;29(5):412–420.
   Web of Science ®Google Scholar
• Zghal FM, Boudiche S, Haboubi S, et al. Diagnostic accuracy of strain imaging in predicting myocardial viability after an ST-elevation myocardial infarction. Medicine. 2020;99(19):e19528.32384424
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Rep Am Coll Cardiol Am Heart Assoc Task Force Clin PractGuidelines. 2017;70(2):252–289.
   PubMed Web of Science ®Google Scholar
• Coronavirus disease (COVID-19). Weekly epidemiological update. 2020 8(31).
   Google Scholar
• Zheng -Y-Y, Ma Y-T, Zhang J-Y, Xie XJNRC. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260.32139904
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar